Initial study will enable further collaboration on the predictive capabilities of StemPrintERPHOENIX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage ...
IMM2510, an anti-PD-L1/VEGF bispecific antibody fusion protein, in patients with R/R STS: A phase Ib expansion study. Gamma secretase inhibitors and desmoid fibromatosis: Lessons from a real world, ...
GCMD says emissions savings from onboard carbon capture could rise to 17.8% once early operational inefficiencies are addressed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback